Mme Docteur GHISLAINE GILL

Bibliographie

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

  2020

  ArticleAnnals of the Rheumatic Diseases

• The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis

  2014

  ArticleJoint Bone Spine

• Improving agreement in assessment of synovitis in rheumatoid arthritis.

  2013

  ArticleJoint Bone Spine

• Three new cases of palmar fasciitis with polyarthritis including a patient with atypical mutilating osteolysis

  2013

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CABINET DU DR GHISLAINE GILL

  91 RUE CAULAINCOURT, 75018 Paris

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• GHU APHP NUP SITE BICHAT C BERNARD

  46 Rue HENRI HUCHARD, 75877 Paris 18e Arrondissement

  ☎ 0140258080Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Total condylar knee arthroplasty. 16- to 21-year results

  Clinical orthopaedics and related research · 1999

  📚 110 citations🎯 RCR 6.20Top 6% NIH
• 2

  Mortality following primary total knee arthroplasty

  The Journal of bone and joint surgery. American volume · 2003

  📚 84 citations🎯 RCR 3.27Top 14% NIH
• 3

  Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

  Arthritis research & therapy · 2013

  📚 81 citations🎯 RCR 2.58Top 20% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Introduction Gout is a common arthritis that occurs particularly in patients who frequently have associated comorbidities that limit the use of conventional therapies. The main mechanism of crystal-induced inflammation is interleukin-1 production by activation of the inflammasome. We aimed to evaluate the efficacy and tolerance of anakinra in gouty patients. Methods We conducted a multicenter retrospective review of patients receiving anakinra for gouty arthritis. We reviewed the response to treatment, adverse events and relapses. Results We examined data for 40 gouty patients (32 men; mean age 60.0 ± 13.9 years) receiving anakinra. Mean disease duration was 8.7 ± 8.7 years. All patients showed contraindications to and/or failure of at least two conventional therapies. Most (36; 90%) demonstrated good response to anakinra. Median pain on a 100-mm visual analog scale was rapidly decreased (73.5 (70.0 to 80.0) to 25.0 (20.0 to 32.5) mm, P <0.0001), as was median C-reactive protein (CRP) level (130.5 (55.8 to 238.8) to 16.0 (5.0 to 29.5) mg/l, P <0.0001). After a median follow-up of 7.0 (2.0 to 13.0) months, relapse occurred in 13 patients after a median delay of 15.0 (10.0 to 70.0) days. Seven infectious events, mainly with long-term use of anakinra, were noted. Conclusions Anakinra may be efficient in gouty arthritis, is relatively well tolerated with short-term use, and could be a relevant option in managing gouty arthritis when conventional therapies are ineffective or contraindicated. Its long-term use could be limited by infectious complications.

Publications scientifiques (24) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche